(THTX) – Globe Newswire
-
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
-
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
-
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
-
Theratechnologies Appoints Elina Tea to its Board of Directors
-
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
-
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
-
Theratechnologies Announces Update on its Preclinical Oncology Research Program
-
Theratechnologies Appoints Jordan Zwick to its Board of Directors
-
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
-
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
-
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
-
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
-
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
-
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
-
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
-
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
-
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
-
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
-
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
-
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
-
Theratechnologies Announces Operational Update
-
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
-
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
-
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
-
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
-
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
-
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
-
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
-
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
-
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
-
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
-
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
-
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
-
Theratechnologies Completes 1-for-4 Reverse Stock Split
-
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
-
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
-
Theratechnologies Announces 1-for-4 Reverse Stock Split
-
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
-
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
-
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
-
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
-
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
-
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Back to THTX Stock Lookup
